文献速递肿瘤 PET/CT

[68Ga]Ga-NY104与[18F]FDG PET/CT在转移性透明细胞肾细胞癌中的前瞻性对比研究

[68Ga]Ga-NY104 PET/CT and [18F]FDG PET/CT in patients with metastatic clear cell renal cell carcinoma (NYCRM): A prospective, single-center, single-arm, comparative imaging trial.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-02-09

这项前瞻性单中心单臂比较影像试验纳入45例病理确诊的转移性透明细胞肾细胞癌(ccRCC)患者,在7天内配对完成CAIX靶向[68Ga]Ga-NY104与标准[18F]FDG PET/CT。基于标准化复合参考标准分析682个病灶,[68Ga]Ga-NY104的灵敏度和特异度均显著优于[18F]FDG,并改变了24%(11/45)患者的临床管理。

要点

  • [68Ga]Ga-NY104病灶水平灵敏度94.4%、特异度98.9%,均显著优于[18F]FDG。
  • [68Ga]Ga-NY104在53%患者中额外识别47个转移区域,24%患者管理改变。
  • 再分期ccRCC时CAIX靶向PET应优先于[18F]FDG。

核心结论

  • 在转移性ccRCC再分期中,[68Ga]Ga-NY104 PET/CT的灵敏度和特异度优于[18F]FDG PET/CT,提示CAIX靶向PET应作为首选PET示踪剂。

研究设计与样本

  • 前瞻性单中心单臂比较影像试验(NYCRM),纳入45例病理确诊的转移性ccRCC患者,7天内配对完成[68Ga]Ga-NY104与[18F]FDG PET/CT。
  • 病灶评估采用标准化复合参考标准(组织病理学、影像学和随访)。
  • 主要终点为病灶水平和区域水平的灵敏度/特异度;次要终点包括SUVmax、肿瘤/本底比值(TBR)和临床管理影响。

主要发现

  • 682个分析病灶中,[68Ga]Ga-NY104灵敏度94.4% vs. [18F]FDG 78.2%(P < 0.001),特异度98.9% vs. 5.5%(P < 0.001)。
  • 区域水平分析证实上述结果:灵敏度97.0% vs. 82.2%,特异度97.5% vs. 10.0%。
  • [68Ga]Ga-NY104的ccRCC病灶摄取更高(SUVmax:12.4 ± 11.8 vs. 7.5 ± 10.7;TBR:15.3 ± 14.6 vs. 4.7 ± 5.5,均P < 0.001),非ccRCC摄取更低(P < 0.001)。
  • [68Ga]Ga-NY104在53%患者中额外识别47个转移区域,并改变24%(11/45)患者的临床管理,包括治疗意图或方式改变。

关键数值与推荐

  • 病灶水平:[68Ga]Ga-NY104灵敏度94.4%、特异度98.9%;[18F]FDG灵敏度78.2%、特异度5.5%(P < 0.001)。
  • 区域水平:[68Ga]Ga-NY104灵敏度97.0%、特异度97.5%;[18F]FDG灵敏度82.2%、特异度10.0%。
  • [68Ga]Ga-NY104的SUVmax为12.4 ± 11.8,TBR为15.3 ± 14.6;[18F]FDG的SUVmax为7.5 ± 10.7,TBR为4.7 ± 5.5(均P < 0.001)。

临床怎么用

  • 对转移性ccRCC进行再分期时,可优先选用CAIX靶向[68Ga]Ga-NY104 PET/CT而非[18F]FDG PET/CT。
  • [68Ga]Ga-NY104可检出[18F]FDG未识别的转移区域,并可能影响治疗意图或方式决策。

局限性

  • 本研究为单中心、单臂设计。
  • 样本量为45例患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study aimed to compare the diagnostic performance of CAIX-targeted [68Ga]Ga-NY104 PET/CT versus standard [18F]FDG PET/CT in metastatic clear cell renal cell carcinoma (ccRCC). METHODS: In this prospective single-center trial (NYCRM), 45 patients with histologically confirmed metastatic ccRCC underwent paired [68Ga]Ga-NY104 and [18F]FDG PET/CT scans within 7 days. Lesions were evaluated using a standardized composite reference (histopathology, imaging, and follow-up). Primary endpoints were lesion- and region-level sensitivity/specificity; secondary endpoints included SUVmax, tumor-to-background ratios (TBR), and clinical management impact. RESULTS: Among 682 analyzed lesions, [68Ga]Ga-NY104 demonstrated superior sensitivity (94.4% vs. 78.2%, P < 0.001) and specificity (98.9% vs. 5.5%, P < 0.001) compared to [18F]FDG. Region-level analysis confirmed these findings (sensitivity: 97.0% vs. 82.2%; specificity: 97.5% vs. 10.0%). [68Ga]Ga-NY104 showed higher ccRCC lesion uptake (SUVmax: 12.4 ± 11.8 vs. 7.5 ± 10.7; TBR: 15.3 ± 14.6 vs. 4.7 ± 5.5, both P < 0.001) and lower non-ccRCC uptake (P < 0.001). Notably, [68Ga]Ga-NY104 identified 47 additional metastatic regions in 53% of patients and altered clinical management in 24% (11/45), including treatment intent or modality changes. CONCLUSION: This prospective head-to-head comparison between [68Ga]Ga-NY104 and [18F]FDG PET/CT in 45 patients with metastatic ccRCC shows superior sensitivity and specificity with [68Ga]Ga-NY104 PETCT than with [18F]FDG. It indicates that CAIX-targeting PET should be the PET tracer of choice over [18F]FDG in restaging ccRCC.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Yan X, Li X, Zheng G, et al. [68Ga]Ga-NY104 PET/CT and [18F]FDG PET/CT in patients with metastatic clear cell renal cell carcinoma (NYCRM): A prospective, single-center, single-arm, comparative imaging trial. Eur J Nucl Med Mol Imaging. 2026. PMID: 41656417. doi:10.1007/s00259-025-07755-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。